Consistently, blockade of the ERK1/2-dependent signaling mediated by MEK1 pharmacologic inhibitors was previously shown to promote anabolism and to protect muscle mass in cancer cachexia, as well as in patients affected with cholangiocarcinoma [26, 63]. Here, MAP2K1 is linked to cancer.